NeurAxis, Inc. Q3 2026 Earnings Call Summary Moby Intelligence Mon, November 9, 2026 at 4:49 PM EST 3 min read NVDA -4.03% NRXS +4.97% Trade NVIDIA on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Revenue growth of 150% was primarily driven by the successful conversion of physician demand into reimbursed IB-Stim treatments following the implementation of the Category I CPT code.
Management is intentionally shifting the patient mix away from discounted financial assistance programs toward full reimbursement, which has significantly improved average selling prices and gross margins.
The company is aligning commercial investment with geographic regions where insurance coverage is most concentrated, prioritizing field resources in states with 40% to 76% coverage.
Recent additions of two large payers expanded the coverage footprint to 147 million lives, providing hospitals with the necessary payer mix confidence to establish dedicated IB-Stim programs.
Management identified short-term implementation hurdles, such as incomplete state Medicaid fee schedules and a specific payer's initial misinterpretation of the multi-device treatment course.
The hiring of a new Chief Commercial Officer and VP of Market Access is intended to resolve reimbursement barriers and improve field execution accountability.
NeurAxis is expanding its direct sales presence by adding at least five full-time territories in markets with established coverage to deepen account utilization.
The company expects recent coverage wins to have a more meaningful revenue impact in 2027 as providers complete the administrative steps required to implement new policies.
Growth in the VA channel is expected to scale independently of commercial insurance policies, with an initial rollout of 10 independent representatives informing potential 2027 expansion.
To address the adult market, the company is initiating a 300-plus patient randomized controlled trial for functional dyspepsia to build the clinical evidence base required for future medical policy coverage.
Management anticipates that increased SG&A and cash burn in the short term will be necessary to secure future growth through expanded sales, marketing, and clinical personnel.
A one-time $4.3 million non-recurring stock compensation charge related to option exchanges significantly impacted GAAP operating expenses but did not affect core cash burn.
The company successfully secured a Federal Supply Schedule contract, enabling a new commercial pathway through the U.S. Department of Veterans Affairs.
Internal prior authorization approval rates increased from 12% in 2025 to 38% as of late October 2026, reflecting improved reimbursement execution.
The company raised approximately $1.7 million through its ATM facility since the end of the third quarter to support liquidity.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Management noted that while one payer had a temporary miscommunication regarding device counts, the other is already showing a positive impact on Q4 results.
The company expects a significant windfall in 2027 as these major policies influence smaller and mid-sized payers across the country.
NeurAxis expects to have 10 to 11 direct sales reps by year-end, with a total commercial-related headcount of approximately 16 including marketing and market access.
New sales representatives are expected to reach material productivity within 90 to 120 days of starting in their territories.
The company currently has the CPT code on 27 state fee schedules and aims to reach 90% coverage of states and territories by the first half of 2027.
Medicaid represents approximately 20% of the patient opportunity at children's hospitals, making fee schedule inclusion critical for institutional program equity and adoption.
